ABSTRACT
O
steoporosis and low bone mass affect Ͼ50 million people in the United States: Every other person older than 50 years of age has low bone mass or osteoporosis. 1 The major sources of morbidity and community health care costs from osteoporosis are related to fractures. By 50 years of age, the remaining lifetime fracture risk is 1 in 2 for women and 1 in 5 for men. 2 By 2025, Ͼ3 million osteoporotic fractures and $25 billion in related health care costs will occur in the United States. 3 Of these, vertebral compression fractures (VCFs) will account for one-quarter of osteoporotic fractures. 3 Some osteoporotic VCFs result in minimal or mild pain. Symptoms typically subside during 6 -8 weeks as healing occurs. For such patients, medical management with analgesics or limiting activities/bed rest, back braces, and physical therapy or a combination of these are the mainstay of treatment. Patients with more severe pain seek medical attention or require hospitalization. Annually, Ͼ60,000 office visits and Ͼ70,000 admissions occur from osteoporotic VCFs in the United States. 4, 5 For these patients, medical management often involves bed rest. As few as 2 days of bed rest lead to bone mass loss 6 ; by 1 week, the rate of bone loss is 50 times the normal age-related rate. 7 After 10 days of bed rest, 15% of aerobic capacity and lower extremity strength is lost, 8 equivalent to 10 years of age-related loss. 8 Adding narcotic anesthesia and the associated adverse effects of sedation, nausea, and constipation further increases physical deconditioning and fall risk and prolongs recovery. After hospitalization, Ͼ50% require ongoing care 4 ; chronic pain occurs in 40%. 9 Thus, while medical management is widely used, there are significant negative effects. In patients with severe pain, vertebral augmentation (vertebroplasty and/or kyphoplasty) may be considered. In general, patients with severe and disabling back pain with correlating physical examination and advanced imaging findings (MR imaging bone marrow edema or bone-scan/SPECT/CT uptake) are selected for treatment. These minimally invasive procedures involve injection of cement (polymethylmethacrylate [PMMA] ) into the VCF. Kyphoplasty involves the additional step of cavity creation; most typically, a balloon tamp is inflated to create a cavity into which PMMA is injected. Both treatments may reduce pain and disability and improve alignment.
Although Ͼ3000 articles have been published on vertebral augmentation, there remains debate on whether it is effective. Our aim was to update clinicians with a focused review of published prospective randomized controlled trials (RCTs) of verte-broplasty and kyphoplasty for osteoporotic fractures. We considered the inclusion of patients in these trials by fracture age: acute (Ͻ6 weeks), subacute (6 -12 weeks) , and chronic (Ͼ12 weeks). We also considered the insights provided by national claims data and recent recommendations of national organizations and medical societies.
Early Observational Data
Successful small European series led to Jensen et al 10 ; P Ͻ .001). Serious complications occurred in Ͻ1%. Similar outcomes were described for kyphoplasty; 1710 patients were pooled. 12 There was significant reduction of the VAS score after treatment (weighted mean difference, Ϫ5.11; 95% CI, Ϫ5.72 to Ϫ4.49). Alignment was also improved, anterior vertebral height was increased, and kyphosis was reduced.
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In 2007, encouraging preliminary data led medical societies to endorse vertebral augmentation as safe and effective for painful osteoporotic VCFs refractory to medical management. 13 However, there were no RCT data, and there were concerns due to the improvement in back pain for most patients, regression to the mean for patients with severe pain, 14 and the influence of the placebo effect. 15 Further evidence from prospective RCTs was required.
Early RCTs
The Vertebroplasty for Painful Chronic Osteoporotic Vertebral Fractures (VERTOS) trial published in 2007 was the first early prospective RCT of vertebroplasty compared with medical management for osteoporotic VCFs. 16 Inclusion criteria were 50 years of age or older, invalidating pain, subacute and chronic fracture age (6 -24 weeks), tenderness on examination, and MR imaging bone marrow edema. Thirty-four patients were enrolled (n ϭ 18 in vertebroplasty, n ϭ 16 in medical management). At 24 hours, there was significant improvement in the VAS score after vertebroplasty (4.7 versus 7.1; difference, Ϫ2.4; 95% CI Ϫ3.7 to Ϫ1.0). At 2 weeks, this was no longer significant. Fourteen (88%) of 16 patients in the medical management arm crossed over to vertebroplasty; no long-term follow-up was possible. The Fracture Reduction Evaluation (FREE) trial from early 2009 is the only multicenter prospective RCT that compared kyphoplasty with medical management for VCFs. 17 Inclusion criteria were 21 years of age or older, moderate back pain (Ն4/10 on the numeric rating scale [NRS], acute and subacute fracture age [Ͻ3 months]), focal tenderness, and MR imaging bone marrow edema. Three hundred patients were enrolled (n ϭ 149 in kyphoplasty, n ϭ 151 in medical management). At 1 month, the primary end point was positive: significantly greater improvement in Short-Form-36 physical component summary scores in the kyphoplasty arm (difference, 5.2 points; 95% CI, 2.9 -7.4; P Ͻ .001). These improvements were durable to 6 months. Patients in the kyphoplasty arm gained 60 days without restricted activity and bed rest. The main limitation of the FREE trial was the lack of blinding, which overestimates treatment benefit due to the placebo response. 18 Moreover, 4 patients had nonosteoporotic fractures.
The FREE investigators later reported 2-year outcome data. There was durable reduction in back pain NRS scores but no difference in the Short-Form-36 or Roland Morris Disability Questionnaire (RDQ) scores at 24 months. 19 Anatomic outcomes were durable:
The 27% anterior height restoration and 3.3°of kyphosis correction gained was maintained. 24 Inclusion criteria were 50 years of age or older, moderate and severe back pain (Ն3/10 points), and fracture age Ͻ1 year confirmed by examination and spine imaging (either plain radiographs or MR imaging). A total of 131 patients were enrolled (n ϭ 68 in vertebroplasty, n ϭ 63 in sham procedures). In both treatment arms, bupivacaine was injected onto the periosteum. In the sham procedure, vertebroplasty was simulated with verbal cues, manual palpation to simulate needle placement, and simulation of the PMMA smell. Baseline fracture age was 16 weeks and 20 weeks in the vertebroplasty and sham procedure arms, respectively. The primary end point was back pain NRS and RDQ scores at 1 month. At 1 month, there was no difference in back pain NRS (P ϭ .19) or RDQ scores (P ϭ .49). There were also no statistically significant differences in secondary outcome measures of pain, disability, and quality of life. Notably, there was a trend toward a higher rate of clinically meaningful improvement in pain (30% reduction) in the vertebroplasty group (64% versus 48%, P ϭ .06). By 3 months, 43% of patients crossed over to vertebroplasty; no longer term comparisons were possible.
There were limitations to INVEST: Forty percent of patients had fractures of Ͻ3 months, while 36% had fractures of Ͼ6 months. Thus, the trial examined acute, subacute, and chronic VCFs. In addition, because MR imaging edema was not a specific requirement, patients were included after plain radiography. However, there may have been adjacent radiographically occult fractures that could have been identified if MR imaging was performed. In addition, enrollment was slow; 1813 patients were screened, 300 declined, and 131 enrolled during 4 years at 11 centers in the United States, United Kingdom, and Australia. Although these centers were chosen on the basis of established vertebroplasty services, INVEST recruited an average of 3 patients per center per year, and sample size estimates were reduced from 249 to 166. In addition, there was a high proportion of patients with Workers Compensation claims. 25 Buchbinder et al 23 published another multicenter doubleblind prospective RCT comparing vertebroplasty with a sham procedure. Inclusion criteria were back pain, fracture age Ͻ1 year, and MR imaging-confirmed fracture line and/or edema. Seventyeight patients were enrolled (n ϭ 38 vertebroplasties, n ϭ 40 sham procedures). In both treatment arms, a 13-ga needle was inserted to the periosteum. In the sham procedure arm, vertebroplasty was simulated with gentle tapping of the needle with the hammer, rotation of the imaging intensifier, and PMMA preparation.
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Baseline fracture age was 9 weeks and 9.5 weeks in the vertebroplasty and sham procedure arms, respectively. The primary outcome was back pain NRS score at 3 months. At 3 months, there was no difference in NRS scores, with no difference at 1 week, 3 months, or 6 months. Additional secondary outcome measures of pain, disability, and quality of life also did not differ.
There were limitations: Thirty-two percent had fractures of Ͻ6 weeks' duration, and one-quarter of patients had fractures between 3 and 12 months (mainly 3-6 months). Thus, acute, subacute, and chronic fractures were included, with limitations similar to those in INVEST. Moreover, a physical examination requirement was not included. From the 468 patients screened, 141 declined and 78 were enrolled during 4 years at 4 Australian centers. Most (68%) were recruited at 1 center; 2 sites enrolled 5 patients. Thus, outcomes may be weighted to this single center. Similar to INVEST, the investigators terminated the trial before reaching the sample size of 82 patients per group for 24-month outcomes; they did achieve their calculated sample size of 24 per group, considered to have 80% power to show a short-term treatment advantage of vertebroplasty. 23 The VERTOS II study followed, another large prospective multicenter RCT designed to compare early vertebroplasty with medical management. 27 Inclusion criteria were 50 years of age or older, moderate back pain (VAS Ն 5), fracture age (Ͻ6 weeks), focal tenderness, and MR imaging bone edema. 28 Two hundred two patients were enrolled (n ϭ 101 for vertebroplasty, n ϭ 101 for medical management). At 1 month, the primary end point was positive: There was a significant improvement in the VAS score in the vertebroplasty arm (VAS, 2.5 versus 4.9; P Ͻ .001), which was durable at 1 year. Patients achieved pain relief almost 3 months faster and gained 120 pain-free days during a year. There were also improvements for secondary outcomes of the RDQ scores (P Ͻ .001) and Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) scores (P Ͻ .001) favoring vertebroplasty.
The main limitation of the VERTOS II trial was the lack of blinding. Further post hoc analysis of the medical cohort revealed that 60% achieved sufficient (VAS Յ 3) pain relief by 12 months, with most within 3 months. 9 There were no predictors to identify the 40% who developed chronic pain. This finding led the investigators to postulate that vertebroplasty may be justified for patients without sufficient pain relief after 3 months of medical management, setting the stage for further trials. Debate persisted about whether vertebroplasty for recent fractures (Յ6 weeks) or severe pain (NRS score Ն8) provided benefit. Thus, data from INVEST and the trials of Buchbinder et al 23, 26 were pooled. Across these trials, 27% (n ϭ 57) had recent-onset (Յ6 weeks) pain and 47% (n ϭ 99) had severe (NRS Ն 8) pain. There was no difference in pain and disability scores at 1 month. 29 Statistical power was increased by pooling the data. However, limitations of the INVEST and Buchbinder trials remained.
In 2011, Farrokhi et al 30 published another RCT of vertebroplasty compared with medical management for osteoporotic VCFs. Inclusion criteria were severe pain, fracture age 4 weeks to 1 year, focal tenderness, MR imaging edema or unhealed fracture cleft, and failure of medical management for 4 weeks. Eighty-two patients were enrolled (n ϭ 40 in vertebroplasty, n ϭ 42 in medical management). There was reduction in the VAS score in the vertebroplasty arm at 1 week (difference, Ϫ3.1; P Ͻ .001) and improvement in quality of life measures. All patients in the vertebroplasty arm were ambulatory after 24 hours compared with 2% after medical management. There was a gain in vertebral body height (mean, 8 mm) and reduction of kyphosis (mean, 8°) after vertebroplasty. Blasco et al 31 followed with their trial of vertebroplasty compared with medical management for osteoporotic VCFs in 2012. Inclusion criteria were moderate pain (VAS Ն 4), fracture age Ͻ1 year, and MR imaging edema or increased uptake on bone scans. One hundred twenty-five patients were enrolled (n ϭ 64 in vertebroplasty, n ϭ 61 in medical management). The mean duration of back pain was 4.7 months; 6 (5%) had fractures of Ͻ6 weeks. At 2 months, there was greater VAS improvement in the vertebroplasty arm compared with the medical arm (P ϭ .017). Rescue anesthesia (intrathecal infusion) was required in 5% of the vertebroplasty arm compared with 25% of the medical arm (P ϭ .002). Both groups had similar improvement in VAS and QUALEFFO scores by 12 months. Limitations include the lack of treatment blinding, the 11% crossover rate to vertebroplasty, and the high loss of follow-up rate (24%).
Recent Prospective Randomized Controlled Data
During these early trials, there remained ongoing doubt regarding the influence of the placebo effect. The sham procedure trials were designed to minimize the placebo effect, but patients with acute, subacute, and chronic fractures causing both moderate and severe pain were enrolled. Moreover, there is now increased recognition of placebo, nocebo, and the concept of active control treatments (such as periosteal local anesthetic injection in the early RCTs) that contribute to success or failure of pain relief. 32 In addition, clinicians performing vertebral augmentation recognized that older patients with severe pain from recent fracture, particularly those admitted to the hospital, may form a subgroup for which vertebroplasty may be of greater benefit. These patients have been included in the recent RCTs. The Vertebroplasty for Acute Painful Osteoporotic fractures (VAPOUR) trial was designed to compare early vertebroplasty with a sham procedure for patients with severe pain.
33 Inclusion criteria were 60 years of age and older, severe back pain (NRS Ն 7), fracture age Ͻ6 weeks, and MR imaging edema or SPECT/CT uptake within 1 week. One hundred twenty patients were enrolled (n ϭ 61 in vertebroplasty, n ϭ 59 in sham procedures). The sham procedure was identical to that in INVEST except that a local anesthetic was injected into the subcutaneous tissues, and the PMMA kit did not emit a smell. There was no difference in the baseline pain NRS score; baseline fracture age was also similar (2.8 versus 2.4 weeks).
The primary end point was the proportion of patients whose NRS pain scores were reduced to Ͻ4 by 14 days. There was a significant treatment advantage in the vertebroplasty arm (44% versus 21%, P ϭ .011) that was durable to 6 months. There were greater reductions in RDQ and QUALEFFO scores favoring vertebroplasty. Notably, 57% of patients were hospital in-patients; the median length of admission was reduced by 5.5 days after vertebroplasty. Anatomic outcomes were also superior: 30% greater vertebral height preservation compared with the sham procedure.
The limitations of VAPOUR include the bias toward a single center, with 85% performed at 1 of 4 recruiting centers. 34 Moreover, 8 of 120 patients did not have the 14-day outcome measure due to delirium, being uncontactable, or revoking consent. However, even if these patients (6 in the vertebroplasty arm) were considered treatment failures, the primary outcome remained significant.
VAPOUR had some important differences compared with the earlier sham procedure trials (Table) , being the first sham procedure RCT that focused on stringent patient selection. Although all patients had fracture ages of Ͻ6 weeks, most (80%) had fractures of Ͻ3 weeks. Second, many (57%) were hospitalized and had vertebroplasty Ͻ7 days from admission. Third, PMMA volumes (mean, 7.5 mL) were much greater than in the trial of Buchbinder et al. 23 Although this trial had specified that 3-4 mL of PMMA would be injected, 26 many patients received less PMMA (mean, 2.8 mL). The INVEST trial investigators did not record PMMA volumes. 35 There are conflicting data on whether higher cement volume or the percentage of vertebral body filled is associated with higher rates of pain relief, with some investigators reporting no association, 36 while others reported a positive cement volume-clinical response association. 37, 38 In addition, the sham procedure in VAPOUR involved subcutaneous local anesthetic injection, closer to a true placebo, 32 compared with the previous trials that used periosteal local anesthetic, an active control treatment that could relieve secondary facet joint pain. 39 Additional small prospective open-label trials were also published in 2016. Yang et al 40 examined elderly patients with early vertebroplasty. Inclusion criteria were 70 years of age and older and moderate and severe pain (VAS Ն 5) with MR imaging edema. One hundred thirty-five patients were enrolled (n ϭ 66 in vertebroplasty, n ϭ 69 in medical management). In the vertebroplasty arm, vertebroplasty was performed at a mean of 8.4 days after symptom onset, with all patients treated Ͻ3 weeks from onset. There was significantly greater improvement in the VAS in the vertebroplasty arm from day 1, which was durable to 1 year. There were improvements in the Oswestry Disability Index and QUALEFFO scores. Limitations included the lack of treatment blinding, the 12% crossover rate, and the small single-institution result limiting generalizability. Leali et al 41 examined postmenopausal women with 1 osteoporotic VCF. Inclusion criteria were fracture age Ͻ6 weeks and MR imaging edema. Four hundred women were enrolled (n ϭ 200 in vertebroplasty, n ϭ 200 in medical management). Baseline fracture age and the VAS in each arm were not reported. Although there was improvement in the vertebroplasty arm at 1 day, there was no difference in the VAS and Oswestry Disability Index at Ն6 weeks. Limitations included the significant paucity of data reported and the lack of treatment blinding.
There is also interest in whether chronic unhealed fractures respond to vertebroplasty as examined by Chen et al in 2014. 42 Inclusion criteria were persistent severe pain for Ͼ3 months and MR imaging edema. A total of 96 patients were enrolled (n ϭ 46 in vertebroplasty, n ϭ 50 on medical management); the mean fracture age was 7 months. From 1 week, there were significantly greater reductions in the VAS score in the vertebroplasty arms that were durable at 1 month, 3 months, 6 months, and 1 year. Similar improvements were evident in RDQ scores. By 1 year, 85% of the patients with vertebroplasty had complete pain relief compared with 35% in the medical arm (P Ͻ .001). Similar limi- tations remain: the lack of treatment blinding and the small single-center design.
Upcoming Evidence
Currently, there remain multiple ongoing trials of vertebral augmentation for osteoporotic fractures. The VERTOS investigators initiated VERTOS IV using the same inclusion criteria as VERTOS II but comparing vertebroplasty with a sham procedure. Enrollment commenced in 2011, with the aim of randomizing 180 patients; results have not been published. 43 The 
Safety Outcomes
Major symptomatic procedural complications from vertebroplasty are significant hemorrhage or vascular injury, spine infection, symptomatic cement pulmonary emboli, symptomatic hemothorax or pneumothorax, new procedure-related fractures, permanent neurologic deficits occurring within 30 days or requiring an operation, and death. 46 Across the RCTs reviewed, these major complications occurred in Ͻ1%, with no procedural mortality. All procedure-related fractures were managed conservatively. 33 Osteomyelitis occurred in 1 patient who did not receive prophylactic antibiotics, 23 and a symptomatic cement leak occurred in 1 patient, requiring decompressive surgery with neurologic recovery. 30 These results have translated to clinical practice:
In a large population-based study of elderly patients (n ϭ 1773), no spinal cord injury or procedural death occurred. 47 Cement leakage outside the vertebra is common when assessed with CT (72% in VERTOS II). 28 Most occur via the end plates, into the disc or local adjacent veins; symptomatic leakage is very rare. During kyphoplasty, compacted bone at the periphery of the cavity is created by balloon tamp inflation, which allows cement injection at lower pressure and higher viscosity, which reduces the rate of leaks. 48 Higher rates of leak are likely with cortical disruption or fracture clefts, use of low-viscosity cement, and higher volume injections. 48 Vertebral augmentation does not increase the baseline risk of new VCFs. Overall, 1 in 5 patients develop a new VCF within 12 months of the initial VCF; the risk is higher in patients with multiple VCFs. 49 Two meta-analyses of published prospective trials found no difference in subsequent VCF risk between the medical management and vertebroplasty cohorts 50, 51 ; baseline low bone mineral density is most consistently associated with increased subsequent VCF risk.
Medical management for VCFs is not always risk-free: Four patients in 2 trials developed spinal cord compression. 33, 40 Three underwent an operation with neurologic recovery; the other remained paraplegic. These occurrences relate to further VCF height loss. In VAPOUR, in almost 50%, further height loss occurred by 6 months in the sham procedure arm. 33 The rates of pneumonia and venous thrombosis were not consistently reported but occurred in 12% in 1 trial. 40 The complications associated with narcotic anesthesia are not reported, but there is growing concern regarding narcotic anesthesia in elderly patients.
Vertebroplasty or Kyphoplasty
Although many RCTs have been published comparing vertebroplasty or kyphoplasty with medical management, there have been few prospective RCTs comparing the safety and efficacy of vertebroplasty with kyphoplasty. The largest RCT was the Kyphoplasty and Vertebroplasty in the Augmentation and Restoration of Vertebral Body Compression Fractures (KAVIAR) trial, which was designed to detect a difference in subsequent radiographic fractures. 53 Although this trial was terminated early due to limited enrollment, 361 patients completed 1-month follow-up (n ϭ 181 vertebroplasty, 180 kyphoplasty procedures). The mean procedural duration was longer with kyphoplasty, with no difference in clinical outcome or symptomatic complications. Similar results have been reported in 2 smaller prospective RCTs. 54, 55 If clinical outcomes are definitively equivalent, the lower procedural cost of vertebroplasty may be favored over kyphoplasty. However, these trials were underpowered to detect differences in clinical outcomes, 56 with KAVIAR reaching only 30% of the enrollment target.
More robust data arise from a recent large systematic review and meta-analysis comparing vertebroplasty and kyphoplasty that included 2838 patients (1454 vertebroplasty and 1384 kyphoplasty procedures) across 29 randomized, prospective nonrandomized, and retrospective comparative studies. 57 There were no differences in back pain or disability pain scores at any time point between vertebroplasty and kyphoplasty. There was no difference in the rate of symptomatic cement leakage, but kyphoplasty was associated with a lower rate of overall cement leakage (P Ͻ .01) and greater kyphosis correction (P Ͻ .01). Limitations included the heterogeneity of results that probably reflects the largely nonrandomized patient cohort included. Further data are required to determine whether subgroups of patients may benefit from kyphoplasty over vertebroplasty.
Hospital Admission
Most patients admitted with a painful VCF are managed conservatively with significant resource use. In a systematic review that included 622,675 hospitalized patients with VCFs, the median length of admission was 10 days; 1 in 4 patients stayed Ն2 weeks. 58 Hospital mortality ranged from 0.9% to 3.5%; up to 50% were discharged into a care facility. 58 Moreover, 1 in 5 patients were re-admitted within 30 days. 59 For hospitalized patients with VCFs, vertebroplasty is associated with a reduced hospital stay and reduced re-admission rates. An analysis of 13,624 hospitalized patients with VCFs from the French Hospital National Database demonstrated that a higher proportion of patients are discharged in 7 days after vertebroplasty compared with medical management (68% versus 47%, P Ͻ .001). 60 A large Taiwanese study using National Health Insurance data for 9238 hospitalized patients with VCFs demonstrated a 2-day-earlier discharge and lower 30-day readmission rates after vertebroplasty.
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Mortality
Excessive mortality risk after VCF ranges from 2% to 42% for 12 months. 61 In an analysis of the Medicare population in the United States (97,142 patients with VCF, 428,956 controls), the mortality rate for patients with VCF was twice that of matched controls. The 3-and 5-year mortality rates for patients with VCF were 46% and 69%, respectively, compared with 22% and 36% for matched controls. 62 The cause of this excessive mortality is unknown. However, death may be an avoidable outcome if the etiology and predictive factors are identified. From data from the Swedish National Register of 16,051 hospitalized patients with VCF, 28% of deaths were considered causally related to the VCF. 63 Vertebral augmentation also reduces in-hospital and longterm mortality after a VCF compared with medical management. In an analysis of 5766 admissions for non-neoplastic VCFs from the Nationwide Inpatient Sample, kyphoplasty halved the rate of in-hospital mortality (OR 0.52, P ϭ .003). 64 There is a similar effect on long-term mortality. In another analysis of 1,038,956 VCFs from the US Medicare dataset, 75,364 patients treated with vertebroplasty and 141,343 treated with kyphoplasty were identified. 65 In the subgroup with osteoporotic VCFs who were propensity matched, the mortality risk was significantly higher after medical management compared with both kyphoplasty (adjusted hazard ratio, 1.70; 95% CI, 1.67-1.74) and vertebroplasty (adjusted hazard ratio, 1.32; 95% CI, 1.29 -1.35); kyphoplasty had a 17% survival benefit compared with vertebroplasty (adjusted hazard ratio, 0.83; 95% CI, 0.80 -0.87). Similar reductions in mortality after vertebral augmentation have been reported in analyses of German 66 and Taiwanese health insurance data. 47 In the Taiwanese dataset that identified 10,785 elderly (older than 70 years) patients hospitalized with a painful VCF, the risk of death was 39% higher in patients receiving medical management (hazard ratio, 1.39; 95% CI, 1.09 -1.78; P ϭ .008) compared with vertebroplasty. Notably, the risk of respiratory failure was also higher after medical management (hazard ratio, 1.46; 95% CI, 1.04 -2.05; P ϭ .028), suggesting that pulmonary impairment may play a role in explaining the excess mortality. For patients medically managed who required opiate anesthesia, the risk of death and respiratory failure was double that of patients who underwent vertebroplasty (hazard ratio death, 1.83; 95% CI, 1.28 -2.60; P ϭ .001; hazard ratio respiratory failure, 2.48; 95% CI, 1.50 -4.11; P Ͻ .001). These increased risks of death and respiratory failure with medical management were observed for up to 12 years of follow-up. The impressive mortality benefit demonstrated in Taiwan could relate to early intervention; 93% received vertebroplasty within 2 weeks of hospital admission.
National Organization and Medical Society Opinions
During the past decade, there has been a clear evolution of the evidence for vertebral augmentation in the treatment of osteoporotic VCFs. 68 In contrast, the National Institute for Health and Care Excellence, which provides evidence-based guidance and advice to the National Health Service in the United Kingdom examined the evidence to November 2011. 69 In April 2013, the National Institute for Health and Care Excellence recommended vertebroplasty and kyphoplasty as treatment options for patients with severe pain after a recent osteoporotic VCF and concluded that it was reasonable to assume that vertebroplasty and kyphoplasty reduce mortality. 70 Similarly, medical societies have also varied in their interpretations of the evidence. In 2010, the American Academy of Orthopaedic Surgeons recommended against vertebroplasty, with a limited recommendation for kyphoplasty for symptomatic osteoporotic VCFs after reviewing the literature to December 2009. 71, 72 By comparison, in their 2014 position papers, the American Association of Neurologic Surgeons, Congress of Neurologic Surgeons, American College of Radiology, American Society of Neuroradiology, American Society of Spine Radiology, Canadian Interventional Radiology Association, Society of NeuroInterventional Surgery, and American Academy of Family Physicians considered vertebral augmentation as a valid treatment option for patients with ongoing pain or disability with medical management. 73, 74 The recent guideline from the Cardiovascular and Interventional Radiologic Society of Europe admits that the evidence for vertebroplasty has been conflicting, but recent data including VAPOUR show a treatment benefit.
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CONCLUSIONS
The evidence for vertebroplasty in the treatment of osteoporotic fractures has evolved with time. Early open-label trials were particularly susceptible to bias and the placebo effect, and the early sham procedure trials were designed to minimize the role of the placebo effect. However, these trials included patients with acute, subacute, and chronic fractures with moderate-to-severe pain. Across the years, evidence has shown that patients subject to more rigorous selection-those with severe pain who are treated Ͻ6 weeks from fracture onset-are good candidates for vertebroplasty. This has been validated by a recent methodologically rigorous sham procedure RCT. Elderly patients hospitalized for painful VCFs are a subgroup that benefits from vertebroplasty; recent data from national datasets indicate vertebroplasty results in earlier hospital discharge, lower re-admission rates, and reduced mortality. 
